Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Liberator Medical Supply was accused of offering doctors kickbacks, such as discounted and free supplies, in exchange for filling prescriptions with its products.
The last count submitted to HHS in October pegged the number at 100 million. Now that figure sits at 190 million, and the company continues its investigation.
The Centers for Medicare & Medicaid Services appealed a court ruling that ordered the agency to change the star rating for UnitedHealthcare's Medicare Part D plans, which had been reduced due to a disputed phone call. CMS has now dropped the appeal.
Tim Noel is taking the reins of the insurance giant in the aftermath of the murder of its previous CEO, Brian Thompson. Noel has been with the company since 2007.
Federal investigations that began in 2019 into Amazon’s potential abuse of power and consumer privacy violations may soon come to fruition with lawsuits to block the company's monopoly status, Politico reported.
One of the 10 largest banks in the country is marketing a new AI-based system aimed at flagging upcoming medical claims that are likely to court rejection by payers.
The state of California and Civica Rx have penned a 10-year deal to deliver insulin at a reduced rate. The medicines will be available in vials and prefilled pens under the CalRx label.
Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025.
Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.
The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.
